PortfoliosLab logoPortfoliosLab logo
Agenus Inc. (AGEN)
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN
US00847G7051
CUSIP
00847G705
IPO Date
Feb 4, 2000

Highlights

EPS (TTM)
-$1.15
Total Revenue (TTM)
$106.83M
Gross Profit (TTM)
$86.00K
EBITDA (TTM)
$33.33M
Year Range
$1.38 - $7.34
Target Price
$7.33
ROA (TTM)
-15.51%
ROE (TTM)
32.93%

Share Price Chart


Loading graphics...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Agenus Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Agenus Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


Loading graphics...

S&P 500 Index

Returns By Period

Agenus Inc. (AGEN) has returned 6.37% so far this year and 121.93% over the past 12 months. Over the last ten years, AGEN has returned -27.48% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.


Agenus Inc.

1D
3.09%
1M
0.30%
YTD
6.37%
6M
-13.25%
1Y
121.93%
3Y*
-51.80%
5Y*
-43.17%
10Y*
-27.48%

Benchmark (S&P 500 Index)

1D
2.91%
1M
-5.09%
YTD
-4.63%
6M
-2.39%
1Y
16.33%
3Y*
16.69%
5Y*
10.18%
10Y*
12.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since Feb 8, 2000, AGEN's average daily return is +0.03%, while the average monthly return is +0.10%. At this rate, your investment would double in approximately 57.8 years.

Historically, 42% of months were positive and 58% were negative. The best month was Jun 2009 with a return of +186.3%, while the worst month was Jul 2024 at -63.9%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 8 months.

On a daily basis, AGEN closed higher 45% of trading days. The best single day was Jun 3, 2009 with a return of +73.2%, while the worst single day was Jul 18, 2024 at -58.8%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026-9.55%17.25%0.30%6.37%
202538.69%-25.00%-47.19%92.03%18.69%33.24%20.79%-24.28%-7.89%3.12%14.86%-31.14%14.60%
2024-19.41%0.42%-13.43%4.48%29.46%6.76%-63.94%-14.74%6.41%-23.36%-18.57%-19.88%-83.45%
20238.75%-21.07%-26.21%1.23%3.31%2.56%-5.00%-9.21%-18.12%-29.20%-2.86%6.54%-64.85%
2022-14.29%-2.17%-8.89%-24.80%-9.73%16.17%32.99%4.65%-24.07%22.44%7.57%-11.11%-25.47%
202115.72%8.70%-32.00%13.60%37.86%28.87%-5.65%19.11%-14.91%-26.86%-17.97%2.22%1.26%

Benchmark Metrics

Agenus Inc. has an annualized alpha of -2.51%, beta of 1.19, and R² of 0.07 versus S&P 500 Index. Calculated based on daily prices since February 09, 2000.

  • This stock participated in 180.39% of S&P 500 Index downside but only 55.10% of its upside — more exposed to losses than it benefited from rallies.
  • R² of 0.07 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
-2.51%
Beta
1.19
0.07
Upside Capture
55.10%
Downside Capture
180.39%

Return for Risk

Risk / Return Rank

AGEN ranks 75 for risk / return — better than 75% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.


AGEN Risk / Return Rank: 7575
Overall Rank
AGEN Sharpe Ratio Rank: 7878
Sharpe Ratio Rank
AGEN Sortino Ratio Rank: 8282
Sortino Ratio Rank
AGEN Omega Ratio Rank: 7777
Omega Ratio Rank
AGEN Calmar Ratio Rank: 7474
Calmar Ratio Rank
AGEN Martin Ratio Rank: 6666
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Agenus Inc. (AGEN) and compare them to a chosen benchmark (S&P 500 Index).


AGENBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

1.20

0.90

+0.30

Sortino ratio

Return per unit of downside risk

2.28

1.39

+0.90

Omega ratio

Gain probability vs. loss probability

1.26

1.21

+0.05

Calmar ratio

Return relative to maximum drawdown

1.79

1.40

+0.39

Martin ratio

Return relative to average drawdown

2.87

6.61

-3.74

Explore AGEN risk-adjusted metrics in detail

Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.

Dividends

Dividend History


Agenus Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading graphics...

Worst Drawdowns

The table below displays the maximum drawdowns of the Agenus Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Agenus Inc. was 99.98%, occurring on Mar 31, 2025. The portfolio has not yet recovered.

The current Agenus Inc. drawdown is 99.95%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.98%Mar 10, 20006302Mar 31, 2025
-23.9%Feb 17, 20003Feb 22, 200012Mar 9, 200015
-6.5%Feb 11, 20001Feb 11, 20002Feb 15, 20003
-4.86%Feb 9, 20001Feb 9, 20001Feb 10, 20002

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading graphics...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Agenus Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Agenus Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for AGEN relative to other companies in the Biotechnology industry. Currently, AGEN has a P/S ratio of 1.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items